参考文献/References:
[1] VANDERPUMP MARK P J. Epidemiology of thyroiddisorders：A comprehensive guide for the clinician[M].The Thyroid and Its Diseases,2019:75-85.
[2] 王卓颖，钱凯．晚期甲状腺癌新辅助治疗进展 [J]．中国实用外科杂志 ,2019,39（3）:275-279．WANG Zuoying，QIAN Kai. Progress of neoadjuvanttherapy for advanced thyroid cancer [J]. ChineseJournal of Applied surgery,2019,39（3）:275-279.
[3] MAO Y，LIU R，ZHOU H，et al. Transcriptomeanalysis of miRNA-lncRNA-mRNA interactions inthe malignant transformation process of gastric cancerinitiation [J]. Cancer Gene Therapy, 2017, 24 (6)：267-275.
[4] ZHU Shiyou,LI Wei,LIU Jingze, et al.Genome-scaledeletion screening of human long non-coding RNAsusing a paired-guide RNA CRISPR-Cas9 library [J].Nature Biotechnology,2016,34(12): 1279-1286.
[5] LI Zheng, SHEN Jianxiong, CHAN M T, et al. TUG1:a pivotal oncogenic long non-coding RNA of humancancers[J]. Cell Proliferation, 2016, 49(4): 471-475.
[6] NIU Yuchun,MA Feng,HUANG Weimei. Long non-coding RNA TUG1 is involved in cell growth andchemoresistance of small cell lung cancer by regulatingLIMK2b via EZH2[J]. Molecular cancer,2017,16(1) : 5.
[7] LIU Jia ,LIN Jieru ,LI Yingqi, et al. Prognostic role oflncRNA TUG1 for cancer outcome: Evidence from 840cancer patients[J].Oncotarget,2017,8(30):50051-50060.
[8] LIU Shankun , LIU Ying , LU Qiang，et al. ThelncRNA TUG1 promotes epithelial ovarian cancer cellproliferation and invasion via the WNT/β-cateninpathway [J]. Onco Targets Ther，2018，11：6845-6851.
[9] 张振，李芬．ceRNA 与肿瘤 [J]．现代检验医学杂志，2016,31（4）:128-130．ZHANG Zhen，LI Fen. ceRNA and tumor [J]. Journalof Modern Laboratory Medicine,2016,31（4）:128-130.
[10] FOK E T,DAVIGNON L, FANUCCHI S，et al. ThelncRNA connection between cellular metabolismand epigenetics in trained immunity[J]. Frontiers inImmunology,2018, 9:3184.
[11] KOCH L. Functional genomics: Screening for lncRNAfunction[J]. Nature Reviews Genetics, 2017, 18(2): 70.
[12] ZHANG Pengfei, CAO Limian, FAN Pingsheng, etal. LncRNA-MIF, a c-Myc-activated long non-codingRNA, suppresses glycolysis by promoting Fbxw7-mediated c-Myc degradation[J]. EMBO Reports, 2016,17(8): 1204-1220.
[13] 白盈盈，朱光旭，潘兴华．长链非编码 RNA 对结直肠癌潜在诊断价值的研究进展 [J]．现代检验医学杂志，2018,33（1）:161-164．BAI Yingying，ZHU Guangxu，PAN Xinghua.Advances in the potential diagnostic value of long non-coding RNA in colorectal cancer [J]. Journal of ModernLaboratory Medicine，2016,33（1）:161-164.
[14] XUE Mei,PANG Huan,LI Xu,et al. Long non-codingRNA urothelial cancer-associated 1 promotes bladdercancer cell migration and invasion by way of thehsa-miR-145-ZEB1/2-FSCN1 pathway[J]. Cancerscience,2016,107(1): 18-27.
[15] CHEN Xuemei,HAN Hongyu,LI Yuqi,et al.Upregulation of long noncoding RNA HOTTIPpromotes metastasis of esophageal squamouscell carcinoma via induction of EMT[J].Oncotarget,2016,7(51): 84480-84485.
[16] SUN Ming, NIE Fengqi, WANG Yunfei, et al.LncRNA HOXA11-AS promotes proliferation andinvasion of gastric cancer by scaffolding the chromatinmodification factors PRC2, LSD1, and DNMT1[J].Cancer Research, 2016, 76(21): 6299-6310.
[17] CAO Jiaqing, HAN Xinyou, QI Xin, et al. TUG1promotes osteosarcoma tumorigenesis by upregulatingEZH2 expression via miR-144-3p[J]. InternationalJournal of Oncology, 2017, 51(4): 1115-1123.
[18] XU Youtao,WANG Jie,QIU Mantang,et al. Upregulationof the long noncoding RNA TUG1 promotesproliferation and migration of esophageal squamouscell carcinoma[J].Tumour Biology,2015,36(3): 1643-1651.
[19] ILIEV R, KLEINOVA R, JURACEK J, et al.Overexpression of long non-coding RNA TUG1predicts poor prognosis and promotes cancer cellproliferation and migration in high-grade muscle-invasive bladder cancer[J]. Tumour Biology, 2016,37(10): 13385-13390.
[20] LI Jun,AN Gang,ZHANG Meng,et al. Long non-codingRNA TUG1 acts as a miR-26a sponge in human gliomacells[J]. Biochemical and Biophysical Research Comm-unications,2016,477(4):743-748.
[21] WANG Liang, ZHAO Zhenxian, FENG Weidong, etal. Long non-coding RNA TUG1 promotes colorectalcancer metastasis via EMT pathway[J]. Oncotarget,2016, 7(32): 51713-51719.
[22] LIN Y H,WU Menghan,HUANG Yahui,et al. Taurineup-regulated gene 1 functions as a master regulator tocoordinate glycolysis and metastasis in hepatocellularcarcinoma[J]. Hepatology (Baltimore, Md.),2018,67(1):188-203.
[23] HAN Xiufu,YANG Yanming,SUN Yongjie,et al.LncRNA TUG1 affects cell viability by regulatingglycolysis in osteosarcoma cells[J]. Gene, 2018, 674:87-92.
[24] 徐苏娟，付子毅，刘丝雨，等．lncRNA TUG1 对卵巢癌细胞 OVCAR3 的增殖迁移及能量代谢的影响[J]．临床肿瘤学杂志 ,2019,24（1）:26-31．XU Sujuan，FU Ziyi，LIU Siyu，et al. Effects oflncRNA TUG1 on proliferation, migration and energymetabolism of OVCAR3 cells[J]. Chinese ClinicalOncology，2019，24（1）：26-31.
[25] BOROUGHS L K, DEBERARDINIS R J. Metabolicpathways promoting cancer cell survival and growth[J].Nature Cell Biology, 2015, 17(4): 351-359.
[26] DANHIER P, BA?SKI P, PAYEN V L, et al. Cancermetabolism in space and time: Beyond the Warburgeffect[J]. Biochimica et Biophysica Acta-Bioenergetics,2017, 1858(8): 556-572.
相似文献/References:
[1]彭继英a,杨红杰b,石晓欣a,等.细针穿刺细胞学检查在甲状腺癌碘-131 治疗后复发诊断中的应用价值[J].现代检验医学杂志,2020,35(01):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
PENG Ji-yinga,YANG Hong-jieb,SHI Xiao-xina,et al.Application Value of Fine Needle Aspiration Cytology in Recurrence
Diagnosis of Thyroid Cancer after Iodine-131 Treatment[J].Journal of Modern Laboratory Medicine,2020,35(06):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
[2]仲亚东,孔德桐,马伯敏.甲状腺癌患者组织及手术前后血清中NR3C2 和ZEB1 表达水平及其与预后价值研究[J].现代检验医学杂志,2023,38(04):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
ZHONG Yadong,KONG Detong,MA Bomin.Study on the Expression Level of NR3C2 and ZEB1 in Thyroid Cancer Tissue and Serum of Patients before and after Surgery and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(06):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
[3]谈玖婷,傅聿明,刘 婧,等.甲状腺癌组织中DCBLD2 和MAP4K3 的表达及与临床病理特征及预后的关系[J].现代检验医学杂志,2024,39(02):34.[doi:10.3969/j.issn.1671-7414.2024.02.007]
TAN Jiuting,FU Yuming,LIU Jing,et al.Expression of DCBLD2 and MAP4K3 in Thyroid Cancer Tissue and Their Relationship with Clinico-pathological Features and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(06):34.[doi:10.3969/j.issn.1671-7414.2024.02.007]